Allergy and immunology occupies a specific place in the prior-authorization landscape: the drug classes are high-cost biologics with real consequences when delayed, but the specialty-specific PA literature is thinner than oncology or rheumatology. What we have is the universal burden — applied to a set of conditions where the clinical downside of a treatment delay can include hospitalization or worse.
The numbers in allergy and immunology
The AMA’s 2024 Prior Authorization Physician Survey provides the most robust cross-specialty data:
- 39 prior authorizations per physician per week.
- 93% of physicians say PA delays patient care.
- 82% say PA can lead patients to abandon treatment.
- 29% report that PA led to a serious adverse event.
That last figure is the sharp one. Allergy and immunology treats conditions — severe asthma, chronic spontaneous urticaria, eosinophilic disease — where inadequate control isn’t just uncomfortable. An asthma exacerbation can be life-threatening. Untreated chronic urticaria can produce angioedema. Delayed access to omalizumab or a comparable biologic while a prior authorization cycles through payer review is not clinically neutral.
Why allergy and immunology is different
- Biologics for immediate-hypersensitivity diseases. Omalizumab (Xolair) for chronic spontaneous urticaria and allergic asthma is high-cost and high-PA. Dupilumab covers atopic dermatitis, eosinophilic esophagitis, and asthma — conditions that often present together in the same patient. Payers require documented disease severity and prior therapy failure for both.
- Step therapy for asthma biologics. Before an anti-IgE or IL-5 pathway biologic can be approved, payers typically require documented failure of high-dose inhaled corticosteroids and, in some cases, additional controller therapy — documentation that has to be assembled per payer, not once.
- Immunotherapy PA complexity. Subcutaneous immunotherapy (SCIT) programs can involve dozens of vials and a multi-year treatment course. Payers vary widely in how they gate allergen immunotherapy — some require allergy testing documentation, some require a demonstrated diagnosis of allergic rhinitis or asthma, some require step-through of pharmacotherapy first.
- Recurring re-authorizations. Biologic maintenance therapy requires periodic re-authorization; a lapsed auth can interrupt a treatment course that has taken months to achieve clinical response.
What it costs
The cost is both operational and clinical. Operationally: staff hours assembling biologic documentation and immunotherapy justifications at roughly $10.81 per manually processed authorization (CAQH 2023), across a practice that manages a complex chronic-disease population with high biologic prescribing. Clinically: the 29% serious-adverse-event rate in the AMA survey is a real signal. When biologics for severe asthma or chronic urticaria are delayed, the patient is living in a disease state that was already inadequate — and escalating exacerbations are the predictable consequence.
How to cut the wait
Biologic authorization documentation in allergy and immunology is structured clinical history: IgE levels, eosinophil counts, prior controller therapy, disease-severity measures. Artificer Health:
- Assembles the clinical packet — diagnosis, severity markers, prior-therapy history, and the payer-specific supporting documentation each biologic requires.
- Matches it to the payer’s criteria so the first submission satisfies that payer’s step-therapy and severity thresholds, reducing the back-and-forth that delays treatment access.
- Tracks re-authorizations for ongoing biologic therapy so the treatment course doesn’t break for a paperwork reason at the exact moment the patient is responding.
For a specialty where 29% of practices have seen a serious adverse event from a PA delay, first-pass approvals in minutes aren’t just an efficiency gain — they’re a patient-safety measure.
Sources: AMA 2024 Prior Authorization Physician Survey (n=1,000); payer medical policies for omalizumab, dupilumab, and anti-IL-5 biologics; CAQH 2023 Index.